Last updated: February 25, 2026
What Is NDC 00536-1447?
The National Drug Code (NDC) 00536-1447 refers to a specific pharmaceutical product. Based on available data, it is identified as Bupropion Hydrochloride Extended-Release (SR), 150 mg. These formulations are typically used to treat depression and smoking cessation.
Market Size and Demand Overview
Sales Data
- Historical sales (2020-2022): The drug experienced stable demand, with average annual revenue around $120 million in primary markets (U.S., Europe, Canada).
- Market penetration: The drug holds approximately 22% of the extended-release bupropion market segment in the U.S.
Competitive Landscape
- Main competitors include Wellbutrin SR (Teva, GlaxoSmithKline) and generic formulations.
- Patent status: The original patent expired in 2009, with multiple generics available.
- Price competition: Generics comprise over 80% of prescriptions, leading to downward price pressure.
Regulatory Factors
- FDA approval for multiple generics has fostered increased access.
- Price regulation policies in key markets influence retail and insurance reimbursement rates.
Price Projections
Current Pricing Landscape
| Market |
Average Wholesale Price (AWP) per 30-day supply |
Medicaid Reimbursement |
Estimated Out-of-Pocket Cost |
| United States |
$25 |
$12 |
$15 |
| Europe |
$28 |
N/A |
$17 |
| Canada |
$27 |
N/A |
$16 |
Source: Red Book Pharmacy's Wholesale Pricing (Q1 2023).
Future Price Trends (2023–2027)
- Market competition: Increased generic availability maintains pressure on prices.
- Regulatory policies: Countries implementing price caps or reimbursement limits may reduce costs.
- Inflation and manufacturing costs: Slight upward pressure expected but offset by competitive market entry.
| Year |
Projected AWP per 30-day supply |
Major Drivers |
| 2023 |
$25 |
Stable demand, generic competition |
| 2024 |
$24 |
Continued price competition |
| 2025 |
$23 |
Market saturation |
| 2026 |
$22 |
Regulatory price caps |
| 2027 |
$21 |
Increased generic competition |
Projection assumptions:
- Continued generic penetration, maintaining prices below $25/AWP.
- No significant patent litigation or formulation innovations.
- Insulin and specialty drug price inflation will not significantly influence this segment.
Premium vs. Generic Pricing
- Brand name (e.g., Wellbutrin SR): Historically priced around $50 per 30-day supply.
- Generic versions: Priced between $15–$25, with minimal margins for brand manufacturers.
Impact of Biosimilars and New Formulations
- No biosimilar or novel formulation projects for this drug are currently in advanced development phases.
- Potential for new formulations (e.g., extended-release variations or combination therapies) remains speculative.
Key Market Drivers
- Prescription volume growth driven by generic affordability.
- Clinician preference for well-established treatments.
- Patient adherence considerations favoring extended-release formats.
Risks and Challenges
- Healthcare policy shifts could limit reimbursement or enforce price controls.
- Patent issues or legal challenges from patent holders could influence supply.
- Market shifts towards alternative therapies or new antidepressant classes.
Summary of Price Trends
| Year |
Average Price Range (per 30-day supply) |
Key Influences |
| 2023 |
$15–$25 |
Competition, generics |
| 2024–2027 |
Declining trend toward $15–$20 |
Market saturation, policy effects |
Market Outlook Summary
The extended-release bupropion segment, represented by NDC 00536-1447, will experience modest price declines due to increasing generic market share. The total U.S. market revenue is expected to remain stable at approximately $120 million annually, with potential slight decreases aligned with price erosion trends. International markets may show similar patterns but could differ based on local regulation and healthcare systems.
Key Takeaways
- The drug (NDC 00536-1447) is a generic bupropion SR formulation, with stable demand and significant generic competition.
- Prices are projected to decline gradually over upcoming years, with average AWP approaching $20 by 2027.
- Regulatory policies and patent statuses are primary factors influencing future pricing.
- Total market value remains steady, driven by prescription volume rather than price increases.
- Market risks include policy interventions and pharmaceutical innovation shifts.
FAQs
1. How does the presence of generics affect the price of NDC 00536-1447?
Generics drive prices downward, with current estimates showing 30-day supply costs around $15–$25, compared to over $50 for brand-name equivalents.
2. What regulatory factors could influence future prices?
Price caps, reimbursement policies, and patent litigations could suppress or stabilize prices.
3. Is there potential for a new formulation to impact the market?
Currently, no new formulations are in advanced development, limiting impact prospects.
4. How does the international market compare to the U.S.?
Prices are slightly higher in Canada and Europe but follow similar trends due to generic availability and regulatory frameworks.
5. What is the main risk to price stability for this drug?
Legal patent disputes, regulatory price controls, and market entry of competing therapies are key risks.
References
- Red Book Pharmacy's Wholesale Pricing. (2023). Truven Health Analytics.
- U.S. Food and Drug Administration (FDA). (2023). Approved Drugs Database.
- IQVIA. (2022). Prescription Market Reports.
- European Medicines Agency (EMA). (2022). Market Authorizations.
- Health Canada. (2022). Drug Price and Reimbursement Reports.
[1] U.S. Food and Drug Administration. (2023). Approved Drugs Database.
